BAXDELA® (TABLET)

Drug Information Related Patent
Hold Company
MELINTA
Learn More
Dosage and Administration
TABLET;ORAL
Specification
EQ 450MG BASE
Indication
BAXDELA® is only used to treat or prevent proven or strongly suspected infections caused by susceptible bacteria.
Use
Instructions for Use
API
DELAFLOXACIN MEGLUMINE
API Structure
We Supply
DELAFLOXACIN MEGLUMINE
Note:

In-house Standard
Facility GMP

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
77281432031/6/19
82528132026/10/2
82738922026/8/6
86480932025/10/7
88719382029/9/23
89695692025/10/7
95392502025/10/7
RE466172029/12/28
API Patent
Patent NoExpiration Date
82528132026/10/2
82738922026/8/6
86480932025/10/7
88719382029/9/23
89695692025/10/7
95392502025/10/7
RE466172029/12/28
HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen-ING. All Rights Reserved.
dcat
Member of
dcat
Top